{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:11:01Z","timestamp":1792188661589,"version":"4.4.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To investigate changes in subfoveal choroidal thickness (SFCT) and their relationship with best-corrected visual acuity and optical coherence tomography parameters after intravitreal dexamethasone implant injection for diabetic macular edema.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Eighty-one eyes treated with dexamethasone implant injection for diabetic macular edema were evaluated for best-corrected visual acuity, central macular thickness, SFCT, and optical coherence tomography parameters at baseline and Weeks 7 and 14.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The mean baseline SFCT significantly decreased at Weeks 7 (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) and 14 (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). At Week 7, each 1-<jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m reduction in central macular thickness and five Early Treatment Diabetic Retinopathy Study letters (\u22120.1 logarithm of the minimal angle of resolution) improvement were associated with SFCT reductions of 0.09 (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.002) and 3.91 (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.044) <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m, respectively. At Week 14, each 1-<jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m reduction in central macular thickness was associated with a 0.14-<jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m reduction in SFCT (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Eyes with good functional and anatomical responses exhibited significantly greater SFCT reductions. Subretinal fluid resulted in greater SFCT changes (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.039) and better best-corrected visual acuity (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.033) at Week 7. A continuous ellipsoid zone\/interdigitation zone layer was associated with a smaller mean SFCT at Week 7 (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.002) and better best-corrected visual acuity at Weeks 7 and 14 (both, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Changes in SFCT after dexamethasone implant injection therapy for diabetic macular edema may predict anatomical and functional outcomes and correlate with optical coherence tomography features that are known as predictors of treatment response.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003029","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T14:05:57Z","timestamp":1607954757000},"page":"1283-1292","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["CHANGES IN SUBFOVEAL CHOROIDAL THICKNESS AFTER INTRAVITREAL DEXAMETHASONE IMPLANT THERAPY FOR DIABETIC MACULAR EDEMA"],"prefix":"10.1097","volume":"41","author":[{"given":"Ka Young","family":"Moon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N Engl J Med"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/jama.293.12.1509","article-title":"Inhibitors of ocular neovascularization: promises and potential problems","volume":"293","author":"van Wijngaarden","year":"2005","journal-title":"JAMA"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000381356","article-title":"Efficacy and safety of intravitreal dexamethasone implant in patients with diabetic macular edema","volume":"233","author":"Guigou","year":"2015","journal-title":"Ophthalmologica"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000356413","article-title":"Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema","volume":"231","author":"Dutra Medeiros","year":"2014","journal-title":"Ophthalmologica"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/aos.13210","article-title":"Viewing the choroid: where we stand, challenges and contradictions in diabetic retinopathy and diabetic macular oedema","volume":"95","author":"Campos","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"e83494","DOI":"10.1371\/journal.pone.0083494","article-title":"Imaging evidence of diabetic choroidopathy in vivo: angiographic pathoanatomy and choroidal-enhanced depth imaging","volume":"8","author":"Hua","year":"2013","journal-title":"PLoS One"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1097\/IAE.0000000000001099","article-title":"Choroidal thickness changes after intravitreal dexamethasone implant injection for the treatment of macular edema due to retinal vein occlusion","volume":"36","author":"Esen","year":"2016","journal-title":"Retina"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/IAE.0b013e318263d11f","article-title":"Choroidal thickness in central serous chorioretinopathy","volume":"33","author":"Kuroda","year":"2013","journal-title":"Retina"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.ophtha.2012.02.022","article-title":"Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results","volume":"119","author":"Yamazaki","year":"2012","journal-title":"Ophthalmology"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/eye.2016.23","article-title":"Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections","volume":"30","author":"Kim","year":"2016","journal-title":"Eye (Lond)"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ophtha.2017.08.031","article-title":"OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant","volume":"125","author":"Zur","year":"2018","journal-title":"Ophthalmology"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1350-9462(01)00005-2","article-title":"Blood flow in the optic nerve head and factors that may influence it","volume":"20","author":"Hayreh","year":"2001","journal-title":"Prog Retin Eye Res"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/IAE.0B013E31822F5678","article-title":"Choroidal thickness in patients with diabetic retinopathy analyzed by spectral-domain optical coherence tomography","volume":"32","author":"Regatieri","year":"2012","journal-title":"Retina"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamaophthalmol.2013.4321","article-title":"Analysis of morphological features and vascular layers of choroid in diabetic retinopathy using spectral-domain optical coherence tomography","volume":"131","author":"Adhi","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2014.09.033","article-title":"Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema","volume":"159","author":"Rayess","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2337\/diacare.25.7.1248","article-title":"Dysfunction of active transport of blood-retinal barrier in patients with clinically significant macular edema in type 2 diabetes","volume":"25","author":"Mori","year":"2002","journal-title":"Diabetes Care"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1167\/iovs.12-11503","article-title":"Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients","volume":"54","author":"Kim","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/IAE.0000000000001645","article-title":"Changes in central choroidal thickness after treatment of diabetic macular edema with intravitreal bevacizumab correlation with central macular thickness and best-corrected visual acuity","volume":"38","author":"Nourinia","year":"2018","journal-title":"Retina"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.exer.2004.09.013","article-title":"Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown","volume":"80","author":"Edelman","year":"2005","journal-title":"Exp Eye Res"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00417-009-1124-4","article-title":"Assessment of serous macular detachment in eyes with diabetic macular edema by use of spectral-domain optical coherence tomography","volume":"247","author":"Koleva-Georgieva","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R22-20250607","first-page":"241","article-title":"Study of aqueous cytokines in patients with different patterns of diabetic macular edema based on optical coherence tomography","volume":"38","author":"Bandyopadhyay","year":"2018","journal-title":"Int Ophthalmol"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/S0161-6420(03)00568-2","article-title":"Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema","volume":"110","author":"Funatsu","year":"2003","journal-title":"Ophthalmology"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.ophtha.2014.07.002","article-title":"A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study","volume":"121","author":"Gillies","year":"2014","journal-title":"Ophthalmology"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/bjophthalmol-2015-307797","article-title":"Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial","volume":"100","author":"Mehta","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"key":"R27-20250607","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/IAE.0b013e3182993f29","article-title":"Diurnal variation in choroidal thickness in relation to sex, axial length, and baseline choroidal thickness in healthy Korean subjects","volume":"34","author":"Lee","year":"2014","journal-title":"Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:04:18Z","timestamp":1749319458000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003029","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}